Skip to content
The Biotechnology Innovation Organization (BIO) 2024 CEO and Investor Conference (a.k.a. #BIOCEO24) took place February 26-27 in New York. The annual event brought together […]
A few more things from #BIOCEO24… Read More »
A lot of great science—and future cures—originates in a university. But while the majority of basic biological research is conducted in an academic setting,
How to succeed at tech transfer – and get great science to patients Read More »
We have gene editing because of women—after all, Nobel Laureates Jennifer Doudna and Emmanuelle Charpentier discovered CRISPR Cas9, which kickstarted the gene-editing revolution. But
Women kickstarted the gene-editing revolution—and continue to lead the way Read More »
Massachusetts Governor Maura Healey’s administration is working with the legislature and a coalition of industry leaders to plan the next reauthorization of the Massachusetts
Gov. Healey plans to reauthorize Massachusetts Life Sciences Initiative Read More »
Moderna CEO Stéphane Bancel testified on Capitol Hill yesterday during a hearing that one U.S. Senator compared to a “show trial” and “public shaming”
Moderna hearing on Capitol Hill is ‘more like a show trial,’ says U.S. Senator Read More »
On Wednesday, Moderna’s CEO will testify before the Senate Health, Education, Labor, and Pensions (HELP) Committee in a hearing with a misleading title, “Taxpayers
4 questions with Moderna President Stephen Hoge Read More »
Eleven years after the first CRISPR patent was filed, we’re anticipating what could be the first approval of a gene therapy based on CRISPR:
‘How do you price a cure?’ and other questions about the CRISPR era Read More »
The Inflation Reduction Act’s drug price controls have been a hot topic during the BIO CEO and Investor Conference—and one that has hampered an
We’re already seeing the impact of drug price controls, say biotech CEOs Read More »
The narrative is that it’s a bad market for biotech, but CEOs and investors told a packed house at the 2023 BIO CEO and
Are SPACs dead? – and other questions about the biotech market outlook Read More »
On Day 1 of the BIO CEO and Investor Conference, a panel—Prioritizing CRO Spending Through a High-Inflation, Sparse-Funding Period—brought together experts to look at
5 things to know about clinical trials Read More »
